Mask Skin Sensitization Testing: Standards, Methods, and Regulatory Requirements

Mask skin sensitization testing evaluates whether the materials and chemicals in face masks can trigger delayed-type hypersensitivity reactions in skin-contacting applications. As an essential component of biocompatibility evaluation under ISO 10993-10 (and its Chinese equivalent GB/T 16886.10), this testing is mandatory for medical mask registration, CE marking, and FDA submissions. This article explains the testing principles, sample preparation, accepted methods, and regulatory applications for mask skin sensitization assessment.

Technical Overview

Skin sensitization testing for face masks is a biocompatibility assessment designed to determine whether extractable chemical substances from mask materials, such as residual monomers, dyes, adhesives, processing aids, antioxidants, and disinfection by-products, can induce allergic contact dermatitis (Type IV delayed hypersensitivity) in end users. Because masks are worn in direct, prolonged, and repeated contact with facial skin, sensitization evaluation is considered a critical endpoint in the biological safety evaluation of these products.

The evaluation framework is defined by the ISO 10993 series of standards for the biological evaluation of medical devices. Specifically, ISO 10993-1 establishes the risk-based evaluation philosophy and categorizes devices by nature and duration of body contact, while ISO 10993-10 specifies the test methods for irritation and skin sensitization. In China, the harmonized national standard GB/T 16886.10 adopts the same technical content, and it is a core requirement for medical mask registration under standards such as YY 0469 (surgical masks) and GB 19083 (protective masks for medical use). Test sample extraction is performed according to ISO 10993-12 / GB/T 16886.12.

Since masks are skin-surface-contacting devices typically used for prolonged durations (more than 24 hours cumulatively, and repeatedly over days or months for reusable products), regulatory authorities in most jurisdictions require documented sensitization data, either through biological testing, chemical characterization with toxicological risk assessment, or a justified combination of both approaches.

Testing Samples

Finished Mask Products

Testing is most representative when performed on the final, sterilized, and packaged product, because manufacturing, dyeing, welding, and sterilization processes (such as ethylene oxide treatment) can introduce or transform sensitizing residues. Common product categories submitted for testing include:

• Medical surgical masks (YY 0469)
• Medical protective masks and respirators, such as N95/KN95/FFP2 types (GB 19083, EN 14683, 42 CFR Part 84 contexts)
• Disposable medical masks (YY/T 0969)
• Civilian daily-use masks (GB/T 32610) where skin-contact safety is claimed
• Reusable textile masks and masks with functional coatings

Components and Materials

When finished product testing is impractical, individual components may be evaluated separately. Relevant components include the inner and outer nonwoven layers (polypropylene spunbond and melt-blown fabrics), middle filter layers, ear loops and head straps, nose bridge strips, adhesives or hot-melt compounds, printing inks, dyes, and any antimicrobial or skincare coatings applied to the skin-facing surface.

Sample Preparation and Extraction

Test extracts are prepared in accordance with ISO 10993-12. Both a polar vehicle (such as physiological saline or water) and a non-polar vehicle (such as sesame seed oil) are typically used to solubilize the full range of extractable substances. Extraction is generally performed under one of the standard condition sets, commonly 37 °C for 72 hours, or alternatively 50 °C for 72 hours or 70 °C for 24 hours, using a standardized ratio of surface area to extraction solvent volume. For masks, testing is normally conducted on the extract rather than the solid material itself, since the skin is exposed to leachable substances rather than to the intact polymer surface.

Testing Items

The core testing item is the assessment of the skin sensitization potential of mask extracts. The evaluation addresses the following specific endpoints:

• Induction of delayed-type (Type IV) hypersensitivity following repeated skin exposure
• Elicitation potential, confirming whether sensitized animals or test systems respond upon re-challenge
• Comparative grading of skin reactions (erythema and edema) against negative and positive controls
• Classification of the material as a sensitizer or non-sensitizer according to the applicable decision criteria of the selected test method

In a complete biocompatibility dossier, sensitization testing is usually performed alongside cytotoxicity (ISO 10993-5) and irritation (ISO 10993-23) to form the minimum biological evaluation package typically expected for skin-contacting devices.

Testing Methods

Guinea Pig Maximization Test (GPMT)

The GPMT is a classical in vivo method described in ISO 10993-10 and OECD Guideline 406. It involves intradermal injection and topical application of the test extract, combined with Freund's complete adjuvant to maximize the immune response (induction phase), followed by a rest period and a topical challenge application. The Magnusson and Kligman grading scale is used to score responses, and results are interpreted against concurrent positive controls (typically a known sensitizer such as mercaptobenzothiazole or hexyl cinnamic aldehyde). GPMT is regarded as a conservative and sensitive method suitable for regulatory submission of mask products.

Buehler Closed Patch Test

The Buehler method uses repeated closed topical patch applications without adjuvant, making it relevant for products whose real-world exposure is via intact skin rather than broken skin. After an induction period of approximately three weeks and a rest phase, the animals are challenged and scored. This method is considered somewhat less sensitive than GPMT but better reflects pure epidermal exposure scenarios typical of mask wear.

Local Lymph Node Assay (LLNA)

The LLNA, specified in ISO 10993-10 and OECD Guideline 429, is a refined in vivo method based on the measurement of lymphocyte proliferation in the draining auricular lymph nodes following ear exposure to the test extract. Animals are not challenged or sensitized systemically, which reduces distress. The stimulation index (SI) is calculated, with an SI of 3 or greater conventionally indicating sensitization. The LLNA also provides dose-response information and can support potency categorization. Radioisotopic and non-radioactive variants (such as BrdU-ELLA) are available.

In Vitro and New Approach Methods (NAMs)

In line with the global trend toward reducing animal testing, several in vitro methods have been validated and adopted into OECD guidelines and are increasingly accepted for device evaluation, particularly when combined in defined approaches or integrated approaches to testing and assessment (IATA):

• DPRA (Direct Peptide Reactivity Assay), OECD TG 442C, addressing molecular initiating events
• KeratinoSens and LuSens (ARE-Nrf2 luciferase assays), OECD TG 442D, addressing keratinocyte activation
• h-CLAT and U-SENS (dendritic cell activation assays), OECD TG 442E, addressing key events in dendritic cell response
• Defined approaches combining these data, including OECD TG 497, which enables a sensitizer or non-sensitizer prediction without animal testing

When in vitro methods are used for masks, the extraction procedure must be adapted to ensure solvent compatibility with the assays, and the testing strategy should be justified within the biological evaluation plan as required by ISO 10993-1 and ISO 10993-2 (animal welfare requirements).

Applications

Skin sensitization test reports for masks serve multiple regulatory and commercial purposes:

• Registration dossiers for medical masks submitted to national medical device authorities, such as NMPA in China, FDA premarket notifications in the United States, and conformity assessment procedures under the EU Medical Device Regulation (MDR)
• CE marking technical documentation and biological evaluation files for masks placed on the European market
• Compliance evidence for product standards including GB/T 32610, YY 0469, and EN 14683-related safety claims
• Material selection and formulation screening during product development, for example when changing dyes, adhesives, elastic materials, or sterilization methods
• Verification after significant process changes, such as a new supplier of melt-blown fabric or a switch from ethylene oxide to irradiation sterilization
• Support for marketing claims such as "skin-friendly" or "dermatologically tested," provided such claims are substantiated by the test scope
• Response to post-market complaints, adverse event investigations, or regulatory authority queries

Tests should be conducted in laboratories accredited to ISO/IEC 17025 and experienced in medical device biocompatibility evaluation, with reports that clearly state sample identification, extraction conditions, method selection rationale, controls, and conclusions.

FAQ

Which standard governs mask skin sensitization testing? The governing methods standard is ISO 10993-10 internationally and GB/T 16886.10 in China, supported by ISO 10993-12 for extract preparation and ISO 10993-1 for the overall evaluation strategy. The specific test protocols reference OECD guidelines where applicable.

Why are both polar and non-polar extracts tested? Mask materials can leach both water-soluble substances (salts, surfactants) and lipophilic substances (plasticizers, oils, dye carriers). Using two vehicles ensures that the biological test exposes the full spectrum of extractable chemicals.

How long does the testing take? In vivo guinea pig methods typically require 6 to 10 weeks including acclimatization, induction, rest, challenge, and reporting. The LLNA generally requires 3 to 5 weeks, while in vitro methods can be completed within 2 to 4 weeks depending on the testing strategy.

How many samples are required? Typical requirements are 30 to 100 finished masks or a minimum material surface area sufficient to prepare the required extract volumes at the standard ratio of 3 cm² per mL (or 0.2 g per mL for non-uniform materials). Exact quantities depend on the selected method and the number of vehicles.

What is the acceptance criterion? A sample is considered non-sensitizing when the test group shows no statistically or biologically significant increase in skin reactions (or stimulation index below 3 in the LLNA) compared with the negative control, while the positive control confirms assay validity. Any positive response requires follow-up evaluation, such as chemical characterization and toxicological risk assessment of identified extractables.

Can in vitro tests fully replace animal tests? For many regulatory purposes, validated in vitro methods and defined approaches under OECD TG 497 are increasingly accepted, especially when supported by chemical characterization. However, the acceptability depends on the target market and the authority reviewing the dossier, so the testing strategy should be defined in advance with the regulatory pathway in mind.

Do civilian or fashion masks also need this test? It is not universally mandatory for non-medical masks, but skin sensitization data is strongly recommended whenever the product makes skin-safety claims, enters markets with relevant requirements, or is intended for children, sensitive populations, or long-duration wear.